Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants


#165775

N/A

GBI Research

$ 3500

In Stock


Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants


Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2018. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. 

The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented. Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. 

The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region. 

GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 9% during the period 2011–2018 from $1,015m in 2011 to $1,879m by 2018. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies. GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. 

Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2011–2018. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts. GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.

Scope

  • The report analyses vaccination patterns, market characterization, regulatory landscape, pipeline analysis, competitive landscape and key M&A trends in the seasonal influenza vaccine market in the APAC region.
  • The report covers
  • Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
  • Market forecasts for the seasonal influenza vaccines from 2011 to 2018
  • Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
  • Key drivers and restraints that have created significant impact on the market.
  • Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
  • Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
  • Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2012 in the seasonal influenza vaccine market.

Reasons to Buy


The report will aid business development and marketing executives strategizing their product launches:

  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.
Table of Contents

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
2.1 Seasonal Influenza Vaccine Market in Asia-Pacific is Set to Grow at a CAGR of 8.9% during the 2011–2018 Forecast Period
2.2 Government Efforts in Asia-Pacific are Driving the Seasonal Influenza Vaccine Market
2.3 Novel Vaccines and New Production Technologies will Revolutionize the Seasonal Influenza Vaccines Market

3 Seasonal Influenza Vaccine Market in Asia-Pacific – Introduction
3.1 GBI Research Report Guidance

4 Seasonal Influenza Vaccine Market in Asia-Pacific – Market Overview
4.1 Market Characterization and Forecasts
4.2 Revenue by Geographical Segmentation

5 Seasonal Influenza Vaccine Market in Asia-Pacific – Australia
5.1 Registration Process and Regulations
5.2 Market Characterization and Forecasts
5.3 Cost of Vaccination
5.4 Vaccination Pattern
5.4.1 Population
5.4.2 Vaccinated Population Contribution
5.4.3 Vaccination Coverage
5.4.4 Number of Doses per Person
5.4.5 Total Number of Doses
5.4.6 Dose Contribution
5.5 Drivers and Barriers
5.5.1 Drivers
5.5.1.1 Government Support for Immunization against Seasonal Influenza
5.5.2 Restraints
5.5.2.1 Seasonal Influenza Vaccines Kept Out of Pharmaceutical Benefits Scheme
5.5.2.2 Incidences of Adverse Reactions after Vaccination

6 Seasonal Influenza Vaccine Market in Asia-Pacific – China
6.1 Registration Process and Regulations
6.2 Market Characterization and Forecasts
6.3 Cost of Vaccination
6.4 Vaccination Pattern
6.4.1 Population
6.4.2 Vaccinated Population Contribution
6.4.3 Vaccination Coverage
6.4.4 Number of Doses per Person
6.4.5 Total Number of Doses
6.4.6 Dose Contribution
6.5 Competitive Landscape
6.6 Drivers and Barriers
6.6.1 Drivers
6.6.1.1 High Awareness due to Pandemic Influenza
6.6.1.2 Availability of Low-cost Flu Vaccines
6.6.2 Barriers
6.6.2.1 Absence of a National Influenza Vaccination Program
6.6.2.2 Lack of Manufacturing Capacity

7 Seasonal Influenza Vaccine Market in Asia-Pacific – Hong Kong
7.1 Registration Process and Regulations
7.2 Market Characterization and Forecasts
7.3 Cost of Vaccination
7.4 Vaccination Pattern
7.4.1 Population
7.4.2 Vaccinated Population Contribution
7.4.3 Vaccination Coverage
7.4.4 Number of Doses per Person
7.4.5 Total Number of Doses
7.4.6 Dose Contribution
7.5 Competitive Landscape
7.6 Drivers and Barriers
7.6.1 Drivers
7.6.1.1 Low Price of Seasonal Influenza Vaccine
7.6.1.2 Government Programs for Seasonal Influenza Vaccination
7.6.2 Restraints
7.6.2.1 Low Government Contribution

8 Seasonal Influenza Vaccine Market in Asia-Pacific – India
8.1 Registration Process and Regulations
8.2 Market Characterization and Forecasts
8.3 Cost of Vaccination
8.4 Drivers and Barriers
8.4.1 Drivers
8.4.1.1 Increasing Awareness of Seasonal Influenza
8.4.1.2 Low-cost Vaccine Expected to be Available in the Future
8.4.2 Barriers
8.4.2.1 Low Vaccination Coverage for Seasonal Influenza
8.4.2.2 Absence of a National Influenza Vaccination Program
8.4.2.3 Absence of Low-cost Domestic Manufacturers of Seasonal Influenza Vaccines in India

9 Seasonal Influenza Vaccine Market in Asia-Pacific – Japan
9.1 Registration Process and Regulations
9.2 Market Characterization and Forecasts
9.3 Cost of Vaccination
9.4 Vaccinated Population
9.4.1 Population
9.4.2 Vaccinated Population Contribution
9.4.3 Vaccination Coverage
9.4.3.1 Number of Doses per Person
9.4.3.2 Total Number of Doses
9.5 Drivers and Restraints
9.5.1 Drivers
9.5.1.1 Influenza Immunization Program
9.5.1.2 Incidences of Pandemic Influenza
9.5.1.3 Rapidly Growing Elderly Population
9.5.1.4 Subsidized Immunization for the Elderly
9.5.2 Barriers
9.5.2.1 Non-reimbursement of Influenza Vaccination Costs
9.5.2.2 Limited Availability Period for Subsidized Vaccines
9.5.2.3 Lack of Scientific Studies Establishing Safety and Efficacy of Flu Vaccines in Japan
9.5.2.4 High Vaccine Cost

10 Seasonal Influenza Vaccine Market in Asia-Pacific – Malaysia
10.1 Registration Process and Regulations
10.2 Market Characterization and Forecasts
10.3 Cost of Vaccination
10.4 Vaccination Pattern
10.4.1 Population
10.4.2 Vaccinated Population Contribution
10.4.3 Vaccination Coverage
10.4.4 Number of Doses per Person
10.4.5 Total Number of Doses
10.4.6 Dose Contribution
10.5 Competitive Landscape
10.6 Drivers and Barriers
10.6.1 Drivers
10.6.1.1 Rapidly Increasing Vaccination Coverage
10.6.2 Barriers
10.6.2.1 Low Government Contribution
10.6.2.2 Low Overall Coverage
10.6.2.3 High Price of Vaccine

11 Seasonal Influenza Vaccine Market in Asia-Pacific – New Zealand
11.1 Registration Process and Regulations
11.2 Market Characterization and Forecasts
11.3 Cost of Vaccination
11.4 Vaccination Pattern
11.4.1 Population
11.4.2 Vaccinated Population Contribution
11.4.3 Vaccination Coverage
11.4.4 Number of Doses per Person
11.4.5 Total Number of Doses
11.4.6 Dose Contribution
11.5 Competitive Landscape
11.6 Drivers and Barriers
11.6.1 Drivers
11.6.1.1 Increasing Vaccination Coverage
11.6.1.2 Government Support for Immunization
11.6.1.3 Low Vaccine Price
11.6.2 Barriers
11.6.2.1 Low Vaccination Coverage for Influenza in Children

12 Seasonal Influenza Vaccine Market in Asia-Pacific – Philippines
12.1 Registration Process and Regulations
12.2 Market Characterization and Forecasts
12.3 Cost of Vaccination
12.4 Vaccination Pattern
12.4.1 Population
12.4.2 Vaccinated Population Contribution
12.4.3 Vaccination Coverage
12.4.4 Number of Doses per Person
12.4.5 Total Number of Doses
12.4.6 Dose Contribution
12.5 Competitive Landscape
12.6 Drivers and Barriers
12.6.1 Drivers
12.6.1.1 Population Growth
12.6.1.2 Rapid Increase in Vaccination Coverage
12.6.2 Restraints
12.6.2.1 Low Government Contribution
12.6.2.2 High Price of Vaccine

13 Seasonal Influenza Vaccine Market in Asia-Pacific – Singapore
13.1 Registration Process and Regulations
13.2 Market Characterization and Forecasts
13.3 Cost of Vaccination
13.4 Vaccination Pattern
13.4.1 Population
13.4.2 Vaccinated Population Contribution
13.4.3 Vaccination Coverage
13.4.4 Number of Doses per Person
13.4.5 Total Number of Doses
13.4.6 Dose Contribution
13.5 Competitive Landscape
13.6 Drivers and Barriers
13.6.1 Drivers
13.6.1.1 Rapidly Increasing Vaccination Coverage
13.6.1.2 Increase in Elderly Population
13.6.2 Barriers
13.6.2.1 Low Government Contribution

14 Seasonal Influenza Vaccine Market in Asia-Pacific – Taiwan
14.1 Registration Process and Regulations
14.2 Market Characterization and Forecasts
14.3 Cost of Vaccination
14.4 Vaccination Pattern
14.4.1 Population
14.4.2 Vaccinated Population Contribution
14.4.3 Vaccination Coverage
14.4.4 Number of Doses per Person
14.4.5 Total Number of Doses
14.4.6 Dose Contribution
14.5 Competitive Landscape
14.6 Drivers and Barriers
14.6.1 Drivers
14.6.1.1 Growth in Elderly Population
14.6.1.2 Government Support for Immunization
14.6.1.3 Low Price of Vaccine
14.6.2 Restraints
14.6.2.1 Stagnating Vaccination Coverage

15 Seasonal Influenza Vaccine Market in Asia-Pacific - Pipeline Analysis
15.1 Pipeline Analysis by Phase
15.2 Product Profiles of Promising Molecules
15.2.1 Optaflu
15.2.1.1 Overview
15.2.1.2 Efficacy
15.2.1.3 Safety
15.2.1.4 Clinical Study Details
15.2.2 GSK2186877A
15.2.2.1 Overview
15.2.2.2 Efficacy
15.2.2.3 Safety
15.2.2.4 Clinical Study Details
15.2.3 Intanza/Flu-ID
15.2.3.1 Overview
15.2.3.2 Efficacy
15.2.3.3 Safety
15.2.3.4 Clinical Study Details
15.2.4 Fluad Pediatric
15.2.4.1 Overview
15.2.4.2 Efficacy
15.2.4.3 Safety
15.2.4.4 Clinical Study Details
15.2.5 FluBlok
15.2.5.1 Overview
15.3 Product Profiles of Marketed Products
15.3.1 Fluarix
15.3.2 Vaxigrip
15.3.3 Influvac
15.3.4 Fluvax
15.3.5 Agrippal

16 Seasonal Influenza Vaccine Market in Asia-Pacific – Competitive Landscape
16.1.1 Sanofi Pasteur
16.1.2 GlaxoSmithKline Biologicals
16.1.3 Abbott Laboratories (Solvay Pharmaceuticals)
16.1.4 CSL Biotherapies
16.1.5 Novartis Vaccines
16.1.6 Crucell N.V. (Berna Biotech)

17 Seasonal Influenza Vaccine Market in Asia-Pacific – Strategic Consolidations
17.1 Overview
17.2 Major Merger and Acquisition Deals, 2007–2012
17.2.1 AstraZeneca Acquires Medimmune
17.2.2 Sanofi-Aventis (now Sanofi) Acquires Acambis
17.2.3 Mymetics Acquires Virosome Biologicals
17.2.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock
17.2.5 Novartis Completes Acquisition of 85% Stake in Zhejiang Tianyuan
17.2.6 Abbott Laboratories Acquires Solvay Pharmaceuticals
17.2.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno
17.2.8 Johnson & Johnson Acquires Crucell
17.2.9 GlaxoSmithKline to Acquire Remaining Interest in Shenzhen GSK-Neptunus Biologicals
17.3 M&A Deals by Geography
17.4 Major Licensing Agreements, 2007–2012
17.4.1 Crucell Enters into License Agreement with Adimmune Corporation
17.4.2 MedImmune Enters into Licensing Agreement with Sanofi Pasteur
17.4.3 Vivalis Enters into Licensing Agreement with GlaxoSmithKline
17.4.4 Vivalis Enters into Licensing Agreement with Nobilon International
17.4.5 MedImmune Enters into Licensing Agreement with GlaxoSmithKline
17.4.6 Hemispherx Biopharma Enters into Licensing Agreement with Biken
17.4.7 MedImmune Enters into Licensing Agreement with Biken
17.4.8 MedImmune Enters into Licensing Agreement with Omninvest
17.4.9 OPKO Health Enters into Licensing Agreement with Academia Sinica
17.4.10 Altravax Enters into Licensing Agreement with Maxygen
17.4.11 Protein Sciences Expands its Licensing Agreement with UMN Pharma for FluBlok and PanBlok
17.4.12 NasVax Extends its Research Agreement with Novartis
17.4.13 iBio Enters into Licensing Agreement with G-Con
17.5 Licensing Deals by Geography

18 Seasonal Influenza Vaccine Market in Asia-Pacific – Appendix
18.1 Market Definitions
18.2 Abbreviations
18.3 Bibliography
18.4 Research Methodology
18.4.1 Coverage
18.4.2 Secondary Research
18.4.3 Primary Research
18.5 Therapeutic Landscape
18.5.1.1 Epidemiology-based Forecasting
18.5.2 Market Size by Geography
18.6 Geographical Landscape
18.7 Pipeline Analysis
18.8 Competitive Landscape
18.8.1 Expert Panel Validation
18.9 Contact Us
18.10 Disclaimer

Table 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue Forecast ($bn), 2011–2018
Table 2: Seasonal Influenza Vaccine Market, APAC Region, Revenue Forecast by Geography ($m), 2011–2018
Table 3: Seasonal Influenza Vaccine Market, Australia, Revenue Forecast ($m), 2011–2018
Table 4: Seasonal Influenza Vaccine Market, Australia, Vaccination Cost Forecast ($), 2011–2018
Table 5: Seasonal Influenza Vaccine Market, Australia, Population Forecast by Age Group (million), 2011–2018
Table 6: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Forecast by Age Group (%), 2011–2018
Table 7: Seasonal Influenza Vaccine Market, Australia, Vaccination Coverage Forecast by Age Group (million), 2011–2018
Table 8: Seasonal Influenza Vaccine Market, Australia, Number of Doses Forecast by Age Group (million), 2011–2018
Table 9: Seasonal Influenza Vaccine Market, China, Revenue Forecast ($m), 2011–2018
Table 10: Seasonal Influenza Vaccine Market, China, Vaccination Cost Forecast ($), 2011–2018
Table 11: Seasonal Influenza Vaccine Market, China, Population Forecast by Age Group (million), 2011–2018
Table 12: Seasonal Influenza Vaccine Market, China, Vaccinated Population Forecast (%), 2011–2018
Table 13: Seasonal Influenza Vaccine Market, China, Vaccination Coverage Forecast (million), 2011–2018
Table 14: Seasonal Influenza Vaccine Market, China, Number of Doses Forecast (million), 2011–2018
Table 15: Seasonal Influenza Vaccine Market, Hong Kong, Revenue Forecast ($m), 2011–2018
Table 16: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Cost Forecast ($), 2011–2018
Table 17: Seasonal Influenza Vaccine Market, Hong Kong, Population Forecast by Age Group, (million), 2011–2018
Table 18: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Forecast by Age Group (%), 2011–2018
Table 19: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Coverage Forecast (‘000), 2011–2018
Table 20: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses Forecast by Age Group (‘000), 2011–2018
Table 21: Seasonal Influenza Vaccine Market, India, Revenue Forecast ($m), 2011–2018
Table 22: Seasonal Influenza Vaccine Market, India, Vaccination Cost Forecast ($), 2011–2018
Table 23: Seasonal Influenza Vaccine Market, Japan, Revenue Forecast ($m), 2011–2018
Table 24: Seasonal Influenza Vaccine Market, Japan, Vaccine Cost ($), 2011–2018
Table 25: Seasonal Influenza Vaccine Market, Japan, Population Forecast by Age Group (million), 2011–2018
Table 26: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage Forecast by Age Group (%), 2011–2018
Table 27: Seasonal Influenza Vaccine Market, Japan, Overall Vaccination Coverage (million), 2011–2018
Table 28: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage by Age Group (million), 2011–2018
Table 29: Seasonal Influenza Vaccine Market, Japan, Number of Doses Forecast (million), 2011–2018
Table 30: Seasonal Influenza Vaccine Market, Japan, Number of Doses Forecast by Age Group (million), 2011–2018
Table 31: Seasonal Influenza Vaccine Market, Malaysia, Revenue Forecast ($m), 2011–2018
Table 32: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Cost Forecast ($), 2011–2018
Table 33: Seasonal Influenza Vaccine Market, Malaysia, Population Forecast by Age Group (million), 2011–2018
Table 34: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Forecast by Age Group (%), 2011–2018
Table 35: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Coverage Forecast by Age Group (‘000), 2011–2018
Table 36: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses Forecast by Age Group (‘000), 2011–2018
Table 37: Seasonal Influenza Vaccine Market, New Zealand, Revenue Forecast ($m), 2011–2018
Table 38: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Cost Forecast (%), 2011–2018
Table 39: Seasonal Influenza Vaccine Market, New Zealand, Population by Age Group Forecast (million), 2011–2018
Table 40: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Forecast (%), 2011–2018
Table 41: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Coverage Forecast (‘000), 2011–2018
Table 42: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses Forecasts (‘000), 2011–2018
Table 43: Seasonal Influenza Vaccine Market, Philippines, Revenue Forecast ($m), 2011–2018
Table 44: Seasonal Influenza Vaccine Market, Philippines, Vaccination Cost Forecast ($), 2011–2018
Table 45: Seasonal Influenza Vaccine Market, Philippines, Population Forecast (million), 2011–2018
Table 46: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Forecast (%), 2011–2018
Table 47: Seasonal Influenza Vaccine Market, Philippines, Vaccination Coverage Forecast (million), 2011–2018
Table 48: Seasonal Influenza Vaccine Market, Philippines, Number of Doses Forecast (million), 2011–2018
Table 49: Seasonal Influenza Vaccine Market, Singapore, Revenue Forecast ($m), 2011–2018
Table 50: Seasonal Influenza Vaccine Market, Singapore, Vaccination Cost Forecast ($), 2011–2018
Table 51: Seasonal Influenza Vaccine Market, Singapore, Population Forecast by Age Group (million), 2011–2018
Table 52: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Forecast by Age Group (%), 2011–2018
Table 53: Seasonal Influenza Vaccine Market, Singapore, Vaccination Coverage Forecast (‘000), 2011–2018
Table 54: Seasonal Influenza Vaccine Market, Singapore, Number of Doses Forecast by Age Group (‘000), 2011–2018
Table 55: Seasonal Influenza Vaccine Market, Taiwan, Revenue Forecast ($m), 2011–2018
Table 56: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Cost Forecast ($), 2011–2018
Table 57: Seasonal Influenza Vaccine Market, Taiwan, Population Forecast by Age Group (million), 2011–2018
Table 58: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Forecast by Age Group (%), 2011–2018
Table 59: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Coverage Forecast by Age Group (million), 2011–2018
Table 60: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses Forecast by Age Group (million), 2011–2018
Table 61: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Filed, 2012
Table 62: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Phase III, 2012
Table 63: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Phase II, 2012
Table 64: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Phase I, 2012
Table 65: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Preclinical, 2012
Table 66: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Discovery Phase, 2012
Table 67: Seasonal Influenza Vaccine Market, APAC Region, Most Promising Vaccines in Clinical Development, 2012
Table 68: Seasonal Influenza Vaccine Market, APAC Region, Major M&A Deals, 2007–2012

Figure 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue Forecast ($bn), 2011–2018
Figure 2: Seasonal Influenza Vaccine Market, APAC Region, Revenue Forecast ($m), 2011–2018
Figure 3: Seasonal Influenza Vaccine Market, APAC Region, Revenue Forecast by Geography ($bn), 2011–2018
Figure 4: Seasonal Influenza Vaccine Market, Australia, Regulatory Authorities, 2012
Figure 5: Seasonal Influenza Vaccine Market, Australia, Drug Approval Process, 2011
Figure 6: Seasonal Influenza Vaccine Market, Australia, Revenue Forecast ($m), 2011–2018
Figure 7: Seasonal Influenza Vaccine Market, Australia, Vaccination Cost Forecast ($), 2011–2018
Figure 8: Seasonal Influenza Vaccine Market, Australia, Population Forecast by Age Group (million), 2011–2018
Figure 9: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Forecast by Age Group (%), 2011–2018
Figure 10: Seasonal Influenza Vaccine Market, Australia, Number of Doses Forecast by Age Group (million), 2011–2018
Figure 11: Seasonal Influenza Vaccine Market, Australia, Drivers and Barriers, 2012
Figure 12: Seasonal Influenza Vaccine Market, China, Regulatory Authorities, 2011
Figure 13: Seasonal Influenza Vaccine Market, China, New Drug Registration Process, 2011
Figure 14: Seasonal Influenza Vaccine Market, China, Revenue Forecast ($m), 2011–2018
Figure 15: Seasonal Influenza Vaccine Market, China, Vaccination Cost Forecast ($), 2011–2018
Figure 16: Seasonal Influenza Vaccine Market, China, Population Forecast by Age Group (million), 2011–2018
Figure 17: Seasonal Influenza Vaccine Market, China, Vaccinated Population Forecast (%), 2011–2018
Figure 18: Seasonal Influenza Vaccine Market, China, Number of Doses Forecast (million), 2011–2018
Figure 19: Seasonal Influenza Vaccine Market, China, Drivers and Barriers, 2012
Figure 20: Seasonal Influenza Vaccine Market, Hong Kong, Regulatory Authorities, 2011
Figure 21: Seasonal Influenza Vaccine Market, Hong Kong, Drug Approval Process, 2011
Figure 22: Seasonal Influenza Vaccine Market, Hong Kong, Revenue Forecast ($m), 2011–2018
Figure 23: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Cost Forecast ($), 2011–2018
Figure 24: Seasonal Influenza Vaccine Market, Hong Kong, Population Forecast by Age Group (million), 2011–2018
Figure 25: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Forecast by Age Group (%), 2011–2018
Figure 26: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses Forecast by Age Group (‘000), 2011–2018
Figure 27: Seasonal Influenza Vaccine Market, Hong Kong, Market Share by Company (%), 2012
Figure 28: Seasonal Influenza Vaccine Market, Hong Kong, Drivers and Barriers, 2012
Figure 29: Seasonal Influenza Vaccine Market, India, Regulatory Authority, 2011
Figure 30: Seasonal Influenza Vaccine Market, India, Common Technical Document Application, 2011
Figure 31: Seasonal Influenza Vaccine Market, India, Drug Approval Process, 2011
Figure 32: Seasonal Influenza Vaccine Market, India, Revenue Forecast ($m), 2011–2018
Figure 33: Seasonal Influenza Vaccine Market, India, Vaccination Cost Forecast ($), 2011–2018
Figure 34: Seasonal Influenza Vaccine Market, India, Drivers and Barriers, 2012
Figure 35: Seasonal Influenza Vaccine Market, Japan, Regulatory Authorities, 2012
Figure 36: Seasonal Influenza Vaccine Market, Japan, Drug Approval Process, 2012
Figure 37: Seasonal Influenza Vaccine Market, Japan, Revenue Forecast ($m), 2011–2018
Figure 38: Seasonal Influenza Vaccine Market, Japan, Population Forecast by Age Group (million), 2011–2018
Figure 39: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage Forecast by Age Group (%), 2011–2018
Figure 40: Seasonal Influenza Vaccine Market, Japan, Number of Doses Forecast by Age Group (million), 2011–2018
Figure 41: Seasonal Influenza Vaccine Market, Japan, Drivers and Barriers, 2012
Figure 42: Seasonal Influenza Vaccine Market, Malaysia, Regulatory Authorities, 2011
Figure 43: Seasonal Influenza Vaccine Market, Malaysia, Drug Approval Process, 2011
Figure 44: Seasonal Influenza Vaccine Market, Malaysia, Revenue Forecast ($m), 2011–2018
Figure 45: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Cost Forecast ($), 2011–2018
Figure 46: Seasonal Influenza Vaccine Market, Malaysia, Population Forecast by Age Group (million), 2011–2018
Figure 47: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Forecast by Age Group (%), 2011–2018
Figure 48: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses Forecast by Age Group (‘000), 2011–2018
Figure 49: Seasonal Influenza Vaccine Market, Malaysia, Market Share by Company (%), 2012
Figure 50: Seasonal Influenza Vaccine Market, Malaysia, Drivers and Barriers, 2012
Figure 51: Seasonal Influenza Vaccine Market, New Zealand, Regulatory Authorities, 2011
Figure 52: Seasonal Influenza Vaccine Market, New Zealand, Drug Approval Process, 2011
Figure 53: Seasonal Influenza Vaccine Market, New Zealand, Revenue Forecast ($m), 2011–2018
Figure 54: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Cost Forecast ($), 2011–2018
Figure 55: Seasonal Influenza Vaccine Market, New Zealand, Population by Age Group Forecast (million), 2011–2018
Figure 56: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Forecast (%), 2011–2018
Figure 57: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses Forecast (‘000), 2011–2018
Figure 58: Seasonal Influenza Vaccine Market, New Zealand, Market Share by Company (%), 2012
Figure 59: Seasonal Influenza Vaccine Market, New Zealand, Drivers and Barriers, 2012
Figure 60: Seasonal Influenza Vaccine Market, Philippines, Regulatory Authorities, 2011
Figure 61: Seasonal Influenza Vaccine Market, Philippines, Drug Approval Process, 2011
Figure 62: Seasonal Influenza Vaccine Market, Philippines, Revenue Forecast ($m), 2011–2018
Figure 63: Seasonal Influenza Vaccine Market, Philippines, Vaccination Cost Forecast ($m), 2011–2018
Figure 64: Seasonal Influenza Vaccine Market, Philippines, Population Forecast (million), 2011–2018
Figure 65: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Forecast (%), 2011–2018
Figure 66: Seasonal Influenza Vaccine Market, Philippines, Number of Doses Forecast (million), 2011–2018
Figure 67: Seasonal Influenza Vaccine Market, Philippines, Market Share by Company (%), 2012
Figure 68: Seasonal Influenza Vaccine Market, Philippines, Drivers and Barriers, 2012
Figure 69: Seasonal Influenza Vaccine Market, Singapore, Regulatory Authorities, 2011
Figure 70: Seasonal Influenza Vaccine Market, Singapore, Drug Approval Process, 2011
Figure 71: Seasonal Influenza Vaccine Market, Singapore, Revenue Forecast ($m), 2011–2018
Figure 72: Seasonal Influenza Vaccine Market, Singapore, Vaccination Cost Forecast ($), 2011–2018
Figure 73: Seasonal Influenza Vaccine Market, Singapore, Population Forecast by Age Group (million), 2011–2018
Figure 74: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Forecast by Age Group (%), 2011–2018
Figure 75: Seasonal Influenza Vaccine Market, Singapore, Number of Doses Forecast by Age Group (‘000), 2011–2018
Figure 76: Seasonal Influenza Vaccine Market, Singapore, Market Share by Company (%), 2012
Figure 77: Seasonal Influenza Vaccine Market, Singapore, Drivers and Barriers, 2012
Figure 78: Seasonal Influenza Vaccine Market, Taiwan, Regulatory Authorities, 2011
Figure 79: Seasonal Influenza Vaccine Market, Taiwan, Drug Approval Process, 2011
Figure 80: Seasonal Influenza Vaccine Market, Taiwan, Revenue Forecast ($m), 2011–2018
Figure 81: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Cost Forecast ($), 2011–2018
Figure 82: Seasonal Influenza Vaccine Market, Taiwan, Population Forecast by Age Group (million), 2011–2018
Figure 83: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Forecast by Age Group (%), 2011–2018
Figure 84: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses Forecast by Age Group (million), 2011–2018
Figure 85: Seasonal Influenza Vaccine Market, Taiwan, Market Share by Company (%), 2012
Figure 86: Seasonal Influenza Vaccine Market, Taiwan, Drivers and Barriers, 2012
Figure 87: Seasonal Influenza Vaccine Market, APAC Region, Pipeline by Phase (%), 2012
Figure 88: Seasonal Influenza Vaccine Market, APAC Region, M&A Deals by Geography (%), 2007–2012
Figure 89: Seasonal Influenza Vaccine Market, APAC Region, Licensing Agreements by Geography, (%), 2007–2012
Figure 90: GBI Research Market Forecasting Model